152 related articles for article (PubMed ID: 21443565)
1. Pigtailed macaque model refinement: topical microbicide safety in the presence of coitus.
Sweeney YT; Angeles RO; Cummings PK; Smith AD; Patton DL
J Med Primatol; 2011 Oct; 40(5):327-34. PubMed ID: 21443565
[TBL] [Abstract][Full Text] [Related]
2. A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model.
Patton DL; Cosgrove Sweeney YT; Paul KJ
Sex Transm Dis; 2008 Oct; 35(10):889-97. PubMed ID: 18607310
[TBL] [Abstract][Full Text] [Related]
3. Macaca fascicularis vs. Macaca nemestrina as a model for topical microbicide safety studies.
Patton DL; Sweeney YC; Tsai CC; Hillier SL
J Med Primatol; 2004 Apr; 33(2):105-8. PubMed ID: 15061723
[TBL] [Abstract][Full Text] [Related]
4. Vaginal and rectal topical microbicide development: safety and efficacy of 1.0% Savvy (C31G) in the pigtailed macaque.
Patton DL; Sweeney YT; Balkus JE; Hillier SL
Sex Transm Dis; 2006 Nov; 33(11):691-5. PubMed ID: 16641825
[TBL] [Abstract][Full Text] [Related]
5. A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model.
Patton DL; Sweeney YT; Paul KJ
Sex Transm Dis; 2009 Jun; 36(6):350-6. PubMed ID: 19556929
[TBL] [Abstract][Full Text] [Related]
6. A comparison of young women's actual and assigned timing of use of a microbicide surrogate.
Tanner AE; Roof KA; Katz BP; Katschke A; Fortenberry JD; Zimet GD
Sex Health; 2012 Sep; 9(4):299-303. PubMed ID: 22877587
[TBL] [Abstract][Full Text] [Related]
7. Cervicovaginal evaluation in macaques used as a model for topical microbicide safety studies.
Scorpio DG; Ruben DS; Liao Z; Hildreth JE; Fletcher CA
J Med Primatol; 2008 Feb; 37 Suppl 1():65-73. PubMed ID: 18269532
[TBL] [Abstract][Full Text] [Related]
8. A guide for standardizing colposcopic observations for the evaluation of topical microbicide products in the pigtailed macaque model.
Patton DL
J Med Primatol; 2012 Feb; 41(1):48-51. PubMed ID: 22017364
[No Abstract] [Full Text] [Related]
9. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites.
van De Wijgert J; Fullem A; Kelly C; Mehendale S; Rugpao S; Kumwenda N; Chirenje Z; Joshi S; Taha T; Padian N; Bollinger R; Nelson K
J Acquir Immune Defic Syndr; 2001 Jan; 26(1):21-7. PubMed ID: 11176265
[TBL] [Abstract][Full Text] [Related]
10. Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial.
Hoffman S; Morrow KM; Mantell JE; Rosen RK; Carballo-Diéguez A; Gai F
Arch Sex Behav; 2010 Jun; 39(3):748-60. PubMed ID: 19636696
[TBL] [Abstract][Full Text] [Related]
11. The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques.
Cole AM; Patton DL; Rohan LC; Cole AL; Cosgrove-Sweeney Y; Rogers NA; Ratner D; Sassi AB; Lackman-Smith C; Tarwater P; Ramratnam B; Ruchala P; Lehrer RI; Waring AJ; Gupta P
PLoS One; 2010 Nov; 5(11):e15111. PubMed ID: 21124745
[TBL] [Abstract][Full Text] [Related]
12. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.
Patton DL; Sweeney YT; Balkus JE; Rohan LC; Moncla BJ; Parniak MA; Hillier SL
Antimicrob Agents Chemother; 2007 May; 51(5):1608-15. PubMed ID: 17353240
[TBL] [Abstract][Full Text] [Related]
13. The importance of the vaginal delivery route for antiretrovirals in HIV prevention.
Ferguson LM; Rohan LC
Ther Deliv; 2011 Dec; 2(12):1535-50. PubMed ID: 22468220
[TBL] [Abstract][Full Text] [Related]
14. Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.
Catalone BJ; Kish-Catalone TM; Budgeon LR; Neely EB; Ferguson M; Krebs FC; Howett MK; Labib M; Rando R; Wigdahl B
Antimicrob Agents Chemother; 2004 May; 48(5):1837-47. PubMed ID: 15105142
[TBL] [Abstract][Full Text] [Related]
15. Topical microbicides for prevention of sexually transmitted infections.
Obiero J; Mwethera PG; Wiysonge CS
Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
[TBL] [Abstract][Full Text] [Related]
16. Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections.
Herold BC; Mesquita PM; Madan RP; Keller MJ
Am J Reprod Immunol; 2011 Mar; 65(3):325-33. PubMed ID: 21143689
[TBL] [Abstract][Full Text] [Related]
17. User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.
Morrow KM; Underhill K; van den Berg JJ; Vargas S; Rosen RK; Katz DF
Arch Sex Behav; 2014 Oct; 43(7):1459-67. PubMed ID: 24452632
[TBL] [Abstract][Full Text] [Related]
18. Clinical safety issues in developing & testing of vaginal microbicides.
Joshi S; Mehendale S
Indian J Med Res; 2006 Jan; 123(1):5-8. PubMed ID: 16567859
[No Abstract] [Full Text] [Related]
19. Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners.
Trottier S; Omar RF; Désormeaux A; Drouin J; Gagnon MT; Vezina F; Guilbert E; Mâsse B; Bergeron MG
Contraception; 2007 Aug; 76(2):117-25. PubMed ID: 17656181
[TBL] [Abstract][Full Text] [Related]
20. Young Women's use of a microbicide surrogate: the complex influence of relationship characteristics and perceived male partners' evaluations.
Tanner AE; Fortenberry JD; Zimet GD; Reece M; Graham CA; Murray M
Arch Sex Behav; 2010 Jun; 39(3):735-47. PubMed ID: 19224355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
